Premium
Risk factors for locoregional relapse after transoral robotic surgery for human papillomavirus–related oropharyngeal squamous cell carcinoma
Author(s) -
Funk Ryan K.,
Moore Eric J.,
García Joaquín J.,
Harmsen W. Scott,
Stoddard David G.,
Vencio Eneida F.,
Foote Robert L.,
Price Katharine A.,
Ma Daniel J.
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24298
Subject(s) - medicine , transoral robotic surgery , chemoradiotherapy , human papillomavirus , oncology , radiation therapy , adjuvant , retrospective cohort study , head and neck squamous cell carcinoma , basal cell , adjuvant radiotherapy , surgery , head and neck cancer
Background Factors predicting locoregional relapse after surgery for oropharyngeal squamous cell carcinoma (SCC) were identified in the pre‐human papillomavirus (HPV) era. We examined whether traditional indications for adjuvant radiotherapy (RT) or adjuvant chemoradiotherapy (CRT) still correlate with locoregional relapse in HPV‐positive patients after transoral robotic surgery (TORS). Methods Retrospective review of oropharyngeal SCC cases identified patients with HPV‐positive tumors who did not receive adjuvant therapy after TORS despite intermediate or high‐risk features. Results Median follow‐up was 26.7 months (range, 4.9–73.1 months). Five of 25 eligible patients (20%) relapsed at a median 4.8 months (range, 3.2–7.8 months). Two of 18 (11%) intermediate and 3 of 7 (43%) high‐risk patients relapsed. Kaplan–Meier 2‐year locoregional relapse‐free survival estimates for intermediate and high‐risk patients were 88% and 57% ( p = .078), respectively. Conclusion Traditional indications for adjuvant RT or CRT were associated with high risk of locoregional relapse in HPV‐positive patients treated with TORS alone. © 2015 Wiley Periodicals, Inc. Head Neck 38 : E1674–E1679, 2016